Results 21 to 30 of about 31,914 (284)

Effects of oral anticoagulants on bone health (systematic literature review)

open access: yesBolʹ, Sustavy, Pozvonočnik, 2023
Background. Osteoporosis is actually today's problem, as it affects the quality and length of life, and increases the risk of fragility fractures, which leads to significant medical, social, and economic problems.
H.V. Mostbauer   +4 more
doaj   +1 more source

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

open access: yes, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P   +17 more
core   +2 more sources

Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.

open access: yesEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2023
AIMS The clinical relevance of common pharmacokinetic interactions with non-vitamin K antagonist oral anticoagulants (NOACs) often remains unclear. Therefore, the impact of P-glycoprotein (P-gp) and CYP3A4 inhibitors and inducers on clinical outcomes in ...
M. Grymonprez   +7 more
semanticscholar   +1 more source

Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome [PDF]

open access: yesRheumatology, 2016
The current treatment of thrombotic APS patients includes long-term anticoagulation with oral vitamin K antagonists (VKAs), with warfarin being the one most commonly used. However, the use of VKAs can be challenging, especially in patients with APS.
SCIASCIA, Savino   +5 more
openaire   +3 more sources

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

open access: yesHellenic Journal of Cardiology, 2021
Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific ...
George Ntaios   +903 more
doaj   +1 more source

The year in cardiology: arrhythmias and pacing. [PDF]

open access: yes, 2020
During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H   +4 more
core   +4 more sources

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2020
Review discusses the problem of non-vitamin K antagonist oral anticoagulants safety in patients with non-valvular atrial fibrillation. Bleeding risk assessment while applying anticoagulant therapy, preventive methods for major bleeding (intracranial ...
E. I. Baranova   +4 more
doaj   +1 more source

Anticoagulants for acute ischaemic stroke [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Counsell, Carl   +2 more
core   +1 more source

Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]

open access: yes, 2019
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ   +7 more
core   +3 more sources

Adaptation of New Oral Anticoagulants for Warfarin Anticoagulated Patient with Traumatic Ongoing Hemorrhage [PDF]

open access: yesJournal of Acute Care Surgery, 2018
The traditional drug for anticoagulation in those with a high risk of thrombosis is a vitamin K antagonist, such as warfarin. On the other hand, this drug has several limitations and hemorrhagic complications.
Jin Bong Ye   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy